The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35426060/
Remarkable advancements have been made in the field of migraine pathophysiology and pharmacotherapy over the past decade. Understanding the molecular mechanism of calcitonin gene-related peptide (CGRP) has led to the...
Conclusion/Relevance: Remarkable advancements have been made in the field of migraine pathophysiology and pharmacotherapy over the past decade. Understanding the molecular mechanism of calcitonin gene-related peptide (CGRP) has led to the discovery of a novel class of drugs, CGRP functional blocking monoclonal antibodies (mAbs), for migraine...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThese are a valuable addition to our tool box, but I hope that insurance companies will catch on.
-
Dr Hamid4yrCGRP-targeted mAbs are effective in the preventive treatment of both chronic and episodic migraine
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35397503/
doi: 10.1186/s10194-022-01396-x. 1 Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy. [email protected]. 2 San Raffaele University, Rome, Italy. [email protected]. 3 Headache and Pain Unit, IRCCS San Raffaele Pisana,...
Conclusions: Fremanezumab seems more effective in real-life than in RCTs. Younger age emerges as a potential response predictor.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is a great validation study.
Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35393301/
1 Ophthalmology, Addenbrooke's Hospital, Cambridge, UK [email protected]. 2 Ophthalmology, Addenbrooke's Hospital, Cambridge, UK. 3 General Surgery, John Radcliffe Hospital, Oxford, UK. 4 Ophthalmology, Epsom and Saint Helier Hospital NHS Trust,...
Conclusion: Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is an important indication to be aware of.
New Perspectives for Developing Therapeutic Bioconjugates of Metabolite-Depleting Enzymes: Lessons Learned Combating Glutamate Excitotoxicity
Source : https://pubs.acs.org/doi/10.1021/acs.biomac.2c00117
Glutamate, the main excitatory neurotransmitter in the central nervous system, plays an essential role in several cognitive activities such as memorizing and learning. Excessive glutamate release and disturbance of glutamate...
Conclusion: This Perspective provides an overview of lessons learned by our group when exploring bioconjugate approaches for combatting glutamate excitotoxicity as an illustration of how research on therapeutic bioconjugates is evolving.
Real-world treatment patterns for CGRP mAb | PPA
What was known before? More than 1 in 4 patients with migraine are eligible for migraine preventive treatments, yet around 1 in 10 patients report using them. Conventional preventive treatments...
Conclusion: Patients on CGRP mAb and specifically galcanezumab showed higher adherence and persistence than patients on SOC migraine preventive treatments.